Trial Profile

A phase I study of reldesemtiv in healthy volunteers to assess higher doses

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Reldesemtiv (Primary)
Indications Spinal muscular atrophy
Focus Adverse reactions

Most Recent Events

08 Aug 2019 According to a Cytokinetics media release, the company is evaluating the data from the study to inform the design of potential future clinical trials.
08 Aug 2019 Status changed from planning to completed, according to a Cytokinetics media release.
22 Jan 2019 According to a Cytokinetics media release, the company expects to initiate this study in the first quarter of 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com